Review
Open access
Sep 2026
Global clinical trial activity in metastatic castration-resistant prostate cancer from January 2020 to March 2026: a landscape analysis
The therapeutic landscape for mCRPC has evolved into a highly diversified and dynamic field, overwhelmingly dominated by early-phase investigations, while radiopharmaceutical therapy (RPT), centered on 177Lu-PSMA, has reached a mature stage of development.
Ling Fan, Shuang Wu, Xing-Xing Xie et al.
· Frontiers in Oncology · 0 citations